<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924296</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1314-203</org_study_id>
    <nct_id>NCT04924296</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis</brief_title>
  <official_title>A Multicentre, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of fSHR-1314 in Adult Patients With Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of SHR-1314 at Week 12 in subjects with proliferation lupus&#xD;
      nephritis in terms of improvement of 24h UPCR, compared to placebo. The study will also&#xD;
      assess the safety and tolerability of SHR-1314 in the patient population over the study&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2021</start_date>
  <completion_date type="Anticipated">September 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1314 subcutaneous administration, a multicentre, randomized, double-blind, parallel, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage change of 24 hours UPCR from baseline to Week 12.</measure>
    <time_frame>at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change of 24 hours UPCR from baseline to Week 24</measure>
    <time_frame>from baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of 24 hours UPCR from Week 12 to Week24</measure>
    <time_frame>from Week 12 to Week24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving 24h UPCR &lt;0.5 g/g at Week 12 and Week 24</measure>
    <time_frame>at Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving renal Complete Response at Week 12 and Week 24</measure>
    <time_frame>at Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pts achieving renal Partial Response at Week 12 and Week 24</measure>
    <time_frame>at Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGA from baseline to Week 12 and Week 24</measure>
    <time_frame>from baseline to Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SLEDAI-2K from baseline to Week 12 and Week 24</measure>
    <time_frame>from baseline to Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1314</intervention_name>
    <description>SHR-1314 s.c. + Steroids</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo s.c. + Steroids</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chinese adult pts (18-65yr), Male or Female&#xD;
&#xD;
          2. BMI≥18 kg/m2 and ≤ 35kg/m2&#xD;
&#xD;
          3. Confirmed diagnosis of LN, renal biopsy report data is within 3-months prior to the&#xD;
             date of ICF is first signed&#xD;
&#xD;
             3.1 Biopsy-proven proliferative lupus nephritis Class III or Class IV, either with or&#xD;
             without the presence of Class V, using the 2003 ISN/RPS criteria.&#xD;
&#xD;
             3.2 24h UPCR ≥ 1 at screening.&#xD;
&#xD;
             3.3 24h UPR ≥ 1.0 g/d，≤ 3.5 g/d.&#xD;
&#xD;
             3.4 eGFR &gt; 45ml/min/1.73m2.&#xD;
&#xD;
          4. SLEDAI-2K≥8.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant medical Problems like myocarditis, pericarditis, severe manifestations of&#xD;
             neuropsychiatric SLE (NPSLE)&#xD;
&#xD;
          2. Subjects who have previously treated by both CYC and MMF (or other forms of&#xD;
             mycophenolate)&#xD;
&#xD;
          3. With a hHistory of using 60 mg/d prednisolone (or equivalent dose) for more than 3&#xD;
             months prior to Baseline&#xD;
&#xD;
          4. History of inflammatory bowel disease or have other ongoing active autoimmune diseases&#xD;
&#xD;
          5. Required management of acute or chronic infections within the past 8 weeks.&#xD;
&#xD;
          6. At screening, history or symptoms of malignancy of any organ system, treated or&#xD;
             untreated, within the past 5 years, regardless of whether there is evidence of local&#xD;
             recurrence or metastases.&#xD;
&#xD;
          7. History of congestive heart failure (New York Heart Association [NYHA] functional&#xD;
             classification ≥III), cerebro-cardiovascular events, or serious bleeding events at&#xD;
             screening and / or randomization that in the judgement of the Investigator prevents&#xD;
             the subject from participating in the study.&#xD;
&#xD;
          8. History of depression and/or suicidal ideation or any suicidal behavior based on an&#xD;
             assessment using the Columbina Suicide Severity Rating Scale (C-SSRS) at screening and&#xD;
             baseline . The subjects will be exluded if any answer to question is &quot;yes&quot; in the&#xD;
             questionnaire orare clinically judged by the investigator to be at risk for suicide&#xD;
&#xD;
          9. Receipt of any IL-17/IL-17R targeted therapy within the past year.&#xD;
&#xD;
         10. Those who have participated in any clinical study for any drug or medical device&#xD;
             within 3 months before screening.&#xD;
&#xD;
         11. Tested positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.&#xD;
&#xD;
         12. All subjects will be tested for tuberculosis status using IGRA and X-ray test.&#xD;
             Subjects with active or latent tuberculosis will be excluded&#xD;
&#xD;
         13. History of severe allergic reaction to contrast agents or biological medicines.Current&#xD;
             drug or alcohol abuse or dependence.&#xD;
&#xD;
         14. History of severe allergic reaction to contrast agents or biological medicines.Current&#xD;
             drug or alcohol abuse or dependence.&#xD;
&#xD;
         15. Pregnant or nursing..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuxian Zhu, M.M</last_name>
    <phone>0518-82342973</phone>
    <email>yuxian.zhu@hengrui.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

